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Abstract
Background: Acute paracetamol poisoning is a rapidly increasing problem in Sri Lanka. The antidotes are
expensive and yet no health economic evaluation has been done on the therapy for acute paracetamol poisoning
in the developing world. The aim of this study is to determine the cost effectiveness of using N-acetylcysteine over
methionine in the management of acute paracetamol poisoning in Sri Lanka.
Methods: Economic analysis was applied using public healthcare system payer perspective.
Costs were obtained from a series of patients admitted to the National Hospital of Sri Lanka with a history of acute
paracetamol overdose. Evidence on effectiveness was obtained from a systematic review of the literature. Death
due to hepatotoxicity was used as the primary outcome of interest. Analysis and development of decision tree
models was done using Tree Age Pro 2008.
Results: An affordable treatment threshold of Sri Lankan rupees 1,537,120/death prevented was set from the
expected years of productive life gained and the average contribution to GDP. A cost-minimisation analysis was
appropriate for patients presenting within 10 hours and methionine was the least costly antidote. For patients
presenting 10-24 hours after poisoning, n-acetylcysteine was more effective and the incremental cost effectiveness
ratio of Sri Lankan rupees 316,182/life saved was well under the threshold. One-way and multi-way sensitivity
analysis also supported methionine for patients treated within 10 hours and n-acetylcysteine for patients treated
within 10-24 hours as preferred antidotes.
Conclusions: Post ingestion time is an important determinant of preferred antidotal therapy for acute paracetamol
poisoning patients in Sri Lanka. Using n-acetylcysteine in all patients is not cost effective. On economic grounds,
methionine should become the preferred antidote for Sri Lankan patients treated within 10 hours of the acute
ingestion and n-acetylcysteine should continue to be given to patients treated within 10-24 hours.
Background
Paracetamol is the most common cause of drug poison-
ing in the world [1] and the single most commonly
taken drug in overdoses that lead to hospital presenta-
tion and admission [2].
Poisoning with paracetamol is an emerging problem in
Sri Lanka with rapidly increasing admissions to the
National Hospital of Sri Lanka (NHSL): from only 35
cases in 2003 to 515 cases in 2005 [3]. Paracetamol poi-
soning is one of the most expensive poisonings
management in Sri Lanka [4,5]. The average cost of
managing a patient with acute paracetamol poisoning
was even higher than the average cost of managing a
organophosphate poisoning patient; the most costly poi-
soning management at the Anuradhapura General Hos-
pital in Sri Lanka [4,5]. However it is important to note
that eighty percent of the current total cost of manage-
ment of acute paracetamol poisoning is due to cost of
antidotes unlike in organophosphate poisoning [5].
Even though paracetamol poisoning has been
researched far more than other pharmaceutical poison-
ings, there is limited literature on the pharmaco-eco-
nomics of treatment. So far no full economic evaluation
on interventions on paracetamol poisoning has been
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and methionine, are available in Sri Lanka. NAC is the
most expensive and also the most commonly used anti-
dote. The evidence on effectiveness of antidotes used in
acute paracetamol poisoning is weak [7]. However, on
t h eb a s i so ft h ec u r r e n tb e s ta v a i l a b l ee v i d e n c eN A Ci s
considered to be more effective than methionine in the
management of patients with acute paracetamol poison-
ing [7]. Considering that NAC is also more costly than
providing methionine, it should be useful to determine
the comparative cost effectiveness of the two treatments,
and whether the additional benefit of NAC over methio-
nine is worth the extra cost. Cost effectiveness analysis
i sb a s e do nt h ep r e m i s et h a ti ti st h ew i d e rc o m m u n i t y
interest which is paramount; therefore extra lives saved
f r o mu s eo fam o r ee x p e n s i v ea n t i d o t eh a v et ob e
balanced against the extra costs involved in doing so. It
is easy to make the management decision; if an inter-
vention is dominant (i.e. the new intervention is less
costly and yields higher benefit). But in situations where
an intervention is not dominant, we have to find out the
point at which the intervention is cost effective. The
question of an intervention is cost-effective depends
upon whether the relevant decision maker is willing and
able to pay the additional costs to achieve the additional
benefits that can be achieved by introducing the alterna-
tive program. The magnitude of this value will be
controversial. In this analysis it was considered that the
program is cost effective if it can gain a year of healthy
life for less than a country’s national income per person
per capita gross national income [8].
The objective of the present cost effectiveness analysis
is to determine the incremental cost effectiveness of
NAC over methionine in the management of acute para-
cetamol poisoning patients (with suicidal intent) in Sri
Lanka.
Methods
Structure of the decision tree model
The evidence on effectiveness of both antidotes; NAC
and methionine depends on the post ingestion time.
According to the best available evidence, all antidotes
are much more effective if given within 10 hours of the
acute ingestion [7].
Therefore we constructed two decision tree models:
for patients treated within 10 hours, and for patients
treated within10 to 24 hours after acute ingestion of
paracetamol (Figure 1). Both models compared use of
methionine and NAC in patients where the risk was
assessed using plasma paracetamol levels according to
the Rumack-Matthew nomogram.
Acute paracetamol poisoning can result in fulminant
hepatic failure which can lead to death. The most fre-
quently applied definition for significant paracetamol
Cost/number of lives saved
a. 
Cost/number of lives saved 
b. 
Figure 1 The decision represented by the node (square) at the left, is between receiving antidote, NAC and methionine when a
patients is presented for treatment within 10 hours (a) and 10-24 hours (b) of the acute ingestion of paracetamol. Each chance event
is shown as a solid circle and represent either the chance of developing liver failure (ALT > 1000 IU) or not developing liver failure. The numbers
on each branch are probabilities and outcome is represented by cost [in million (M) rupees (LKR)] per number of lives saves (1000 hypothetical
patients in each arm were considered) at the terminal node (rectangular). The probabilities and outcomes are explained in Table 1.
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AST) > 1000 U/L at any time [9,10].
Therefore the decision tree model adopted death fol-
lowing hepatotoxicity (ALT or AST > 1000 U/L) as the
final outcome measure (Figure 1).
Population considered
The analysis was applied to patients admitted to the
National Hospital of Sri Lanka (NHSL). The ethics
approval was obtained from ethical review boards of the
NHSL and the Faculty of Medicine, Colombo. In Sri
Lanka healthcare is free at the point of delivery. There-
fore the analysis was done from the public healthcare
system payers’ perspective. The time horizon was 2006
and the analysis was performed with reference to 1000
hypothetical patients in each arm.
Data and assumptions on costs and effectiveness of
antidotes
Costs
The direct costs linked to the treatment options were
measured as the total cost of drug treatment and hospi-
talisation. The total cost of drug treatment includes the
cost of NAC/methionine (obtained from the medical
supplies division of Sri Lanka), cost of hospital stay
(obtained from accounts branch of the NHSL and follow
up of case series) and cost of person hours (obtained
from accounts branch of the NHSL and follow up of
case series). The cost of antidotal therapy was based on
t h eu s u a lN A C( I VN A C3 0 0m g / k go v e r2 0 . 2 5h o u r s )
and methionine regimen(2.5 g every four hours for four
doses) used in Sri Lanka. The costs in LKR (Sri Lankan
rupees) (100 LKR = 1 US dollar) of items included in
the analysis are given in Additional file 1: annexure1.
Effectiveness data
Antidotal effectiveness data was obtained from the sys-
tematic review and meta-analysis on the interventions for
paracetamol poisoning by Brok et al. 2002 and 2006 [6,7].
The meta analysis included randomised controlled trials
(RCTs), quasi-RCTs, RCTs with volunteers and observa-
tional studies. According to the review, no RCTs were of
high quality. Further, no RCT compared NAC with
methionine or no treatment for the relevant time frame
(within24 hours of the acute ingestion) for this analysis.
The review provided an exploratory analysis on antidotes
and gave pooled probabilities for developing hepatotoxi-
city and death following acute paracetamol poisoning in
patients with plasma paracetamol levels above possible or
probable risk line of the nomogram [10,11]. Summary of
the studies included in the exploratory analysis are given
in Additional file 2: annexure 2 [9-21].
Incremental cost effectiveness
The total costs and outcomes for each treatment arm
were presented. The expected value of each
management alternatives identified at the root. The
incremental cost effectiveness ratio (ICER) for two alter-
native treatments was calculated (incremental analysis
produces a summary measure of relative efficiency) by
dividing the cost difference by the outcome difference.
ICER = (Cost of NAC − cost of methionine)/(Outcome for NAC − outcome for methionine)
When there was no difference in outcome between
management alternatives, cost minimisation analysis was
done and the least costly management alternative was
chosen.
Development of decision tree models and the analysis
were done using Tree Age Pro Excel healthcare 2008
software, Serial number GXT2J-2B6KK-3D3DV-G.
Discounting and sensitivity analysis
Acute paracetamol poisoning is an acute condition and
costs and outcomes occur during a short span of time:
two to ten days. Therefore costs or outcomes were not
discounted to adjust for elapsed time between expenditure
and outcome when ICERs are calculated. When treatment
threshold value was calculated, future income of the study
patients were considered and therefore it was discounted
at the rate of 3.5% to bring it to the present value [22],
One-way-sensitivity analysis was done by increasing
and decreasing costs and mortality by 50% and also by
taking the upper and lower confidence interval of the
probability on the systematic review estimates of mortal-
ity and hepatotoxicity with each antidote. Multi- ways
sensitivity analysis was done to examine the worst com-
bination of the single factors for both NAC and methio-
nine in both time periods.
Results
Medical care cost
When a 60 kg patient is treated with NAC and does not
develop hepatotoxicity, the cost to the healthcare system
was 15,038 rupees. However if the patient develops
hepatotoxicity, the cost ris e st o3 4 , 3 2 9r u p e e sd u et o
infusion of additional NAC and supportive care. The
total cost for the methionine option was 2,839 rupees
when patients do not develop hepatotoxicity and 22,481
when the patient develops hepatotoxicity. The break-
down on direct medical care costs are given in Addi-
tional file 1: annexure 1.
Outcome data
The exploratory analysis of the systematic review pooled
studies together and gave pooled probabilities as shown
in Table 1[7]. The probability for death following the
use of both antidotes was zero for patients treated
within 10 hours of the acute ingestion. However, the
95% CI of the case-fatality had an upper CI of 0.5% for
NAC and 2.4% for methionine.
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The mean per capita income for a Sri Lankan in 2006
was LKR 6,463/month [23]. The average age for the
case series of patients was 20 years and the average
number of working years for a Sri Lankan is 55 years
which is the retirement age. When patients poisoned
with paracetamol dies at the age of 20, the society will
lose average earning at the rate of percapita income per
month up to the retirement age. Therefore the dis-
counted present value of a life saved at the age of 20
would be LKR 1,537,120
(Discounted present value = ∑
35-1 77556n (1-0.035)
n)
and this value was used as the treatment threshold value
to prevent a death due to acute paracetamol poisoning
in Sri Lanka. Therefore the study considered that it is
cost effective to prevent an additional death by NAC at
a cost of ≤ LKR 1,537,120.
Baseline results
The decision tree models with expected outcomes for
patients presenting within 10 and 10-24 hours is given
in Figure 1.
The incremental cost effectiveness ratios reveal how
much it would cost to prevent an extra death by shifting
t ot h em o r ec o s t l ya n t i d o t e( N A C )f r o mt h ec h e a p e r
alternative antidote (methionine). When treated within
10 hours of the acute ingestion, the incremental cost for
treatment with NAC over methionine came to LKR
11,588,680, but outcome resulted from alternative inter-
ventions were similar. Therefore base line ICER was not
calculated for this group and cost minimisation analysis
was done (Table 2).
Cost effectiveness analysis was done for patients treated
within 10 to 24 hours, the ICER for this group of patients
was LKR 316,182 per life saved (below the threshold
value) where the incremental cost was LKR 8,726,620
and additional lives saved by NAC was 28 (Table 2).
Sensitivity analysis
One way sensitivity analysis
Incremental cost effectiveness ratios for one way sensi-
tivity analysis, taking mortality as outcome measure are
given in Table 2.
Multi-way-sensitivity analysis
According to the base-case analysis, methionine was the
lease costly antidote for patients treated within 10 hours
and NAC had an ICER below the threshold value for
patients treated within 10 to 24 hours after ingestion.
The robustness of this decision was further tested by
assessing the worse case for methionine when given
within 10 hours and the worse case for NAC when
given 10-24 hours in a multi-way sensitivity analysis.
Worse case analysis for methionine within 10 hours
gave an ICER of LKR 2,718,784 for NAC. Worse case
analysis for NAC given within 10-24 hours showed
dominance for methionine where methionine saved 42
more lives at a lower cost.
Discussion
The most important factor influencing total cost in the
management of acute paracetamol poisoning in Sri
Lanka is the antidotal therapy. This cost pattern would
also be observed in other developing country settings
where hospital stay and human resources are cheaper.
Economic modeling should inform the most cost effec-
tive way of using these two antidotes which can reduce
the total cost of management in developing country
settings.
Table 1 Probability for hepatotoxicity and death, when antidotes are administered within 0-10 and 10-24 hours from
the acute ingestion
Probability for
AST/ALT > 1000 IU/l (n/N)
[6,7]
Probability for death (n/N) Note
IV NAC 300 mg/kg over 20.25 hours
Within 10 hours 4% (13/315) 0
†(0/13) *
(95% CI 2.5 to 7.0) (95% CI 0 to 24)
Within 10-24 hours 20% (67/322) 9%
‡ (6/67) *
(95% CI 17 to 26) (95% CI 3.8 to 18)
Methionine 1 g 4 hourly 4 doses
Within 10 hours 9% (13/143) 0
† #
(95% CI 4.5 to 15) (95% CI 0 to 24)
Within 10-24 hours 38%(17/41) 12%
Π(2/17) #
(95% CI 26.3 to 57.9) (95% CI 2 to 36)
* Probabilities were derived by pooling results of Prescott et al. 1979, Smilkstein et al. 1988, Burkhart et al. 1995, Buckley et al. 1999, Parker et al. 1990, Smilkstein
et al. 1991, Woo et al. 2000, Ayonrinde et al. 2005 and Kerr et al. 2005 [9-17]. # Probabilities were derived by pooling results of Prescott et al. 1979, Crome et al.
1976, Hamlyn et al. 1981, Prescott et al. 1976 and Vale et al. 1981 [9,18-21]. † No patient treated (NAC/methionine) within 10 hours died due to hepatototoxicity,
therefore the probability of death due to hepatotoxicity was zero
Senarathna et al. BMC Clinical Pharmacology 2012, 12:6
http://www.biomedcentral.com/1472-6904/12/6
Page 4 of 7The most suitable economic analysis for patients trea-
ted within 10 hours of the acute ingestion is the cost
minimization analysis, as the evidence suggests the
probability of death is zero for patients treated with
either antidote. With this premise, methionine is clearly
the least costly alternative for this group of patients.
One-way sensitivity analysis and multi-way sensitivity
analysis calculated ICERs (on instances where there is
an outcome difference) were above our pre-defined
threshold for an acceptable cost per life saved by NAC.
Therefore, methionine is the antidote of choice for
patients treated within 10 hours.
The ICER for NAC for patients presenting within 10-
24 hours was LKR 316,182 for a death prevented. This
is a value much lower than the treatment threshold
value and suggests the use of NAC in preference to
methionine is very cost-effective. One way sensitivity
analysis in all instances had ICERs lower than the
threshold value except when the lower confidence inter-
val for death following methionine was considered
where it showed dominance for methionine.
Worse case analysis for NAC also indicated domi-
nance for methionine. Therefore the conclusion ranged
from dominance for methionine to NAC being cost
effective. However in most of the sensitivity analysis and
i nt h eb a s ec a s ea n a l y s i st h eI C E Rf o rN A Cw a sm u c h
lower than the threshold value. Therefore use of NAC
for patients presenting within 10-24 hours of the acute
ingestion appears to be a cost effective option in Sri
Lanka.
The effectiveness data for the decision tree was based
on the systematic review and meta analysis by Brok et
al. 2006. The meta-analysis referred to 10 studies to
produce estimates of effectiveness in respect to these
t w oa n t i d o t e s ;f i v es t u d i e sf o rN A C ,f o u rs t u d i e sf o r
methionine and one study on both antidotes. According
to the levels of evidence and grade of recommendation
proposed by Cook et al. 1992 [24], studies used for
methionine were in grade B(1), grade C(1) and grade D
(2), studies used for effectiveness of NAC were in grade
B(1), Grade D(2)and grade E(2) and the study on both
NAC and methionine was grade D quality.
The meta-analysis did not use any studies which pro-
vided grade A recommendations and eight out of 10
studies were in grade D or worse. An RCT directly com-
paring these two antidotes would provide much better
Table 2 Incremental cost per life saved for baseline data and following one way sensitivity analysis (Number of lives
saved as the final outcome measure)
Incremental cost per life saved(LKR/Life saved)
0-10 hrs 10-24 hrs
Baseline results Not applicable
‡ 316,182
One way sensitivity analysis results
Increasing by 50%
NAC deaths Not applicable
‡ 469,173
NAC cost Not applicable
‡ 565,805
Methionine deaths Not applicable
‡ 173,147
Methionine cost Not applicable
‡ 265,107
Decreasing by 50%
NAC deaths Not applicable
‡ 238,432
NAC cost Not applicable
‡ 55,312
Methionine deaths Not applicable
‡ 1,818,046
Methionine cost Not applicable
‡ 366,486
Upper confidence interval(CI)
NAC deaths Dominance for methionine
† 909,023
NAC hepatotoxicity Not applicable
‡ 445,229
Methionine deaths 5,365,130 73,456
Methionine hepatotoxicity Not applicable
‡ 94,349
Lower confidence interval(CI)
NAC deaths Not applicable
‡ 229,648
NAC hepatotoxicity Not applicable
‡ 268,907
Methionine deaths Not applicable
‡ Dominance for methionine
†
Methionine hepatotoxicity Not applicable 836,480
‡ The outcome resulted from alternative interventions were similar therefore cost effectiveness ratios were not calculated.
† Methionine shows strong dominance for a decision as the incremental effectiveness was lower while the incremental cost is higher for NAC (methionine saves
more lives at a lower cost)
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should be strongly supported. The trial could not easily
be blinded due to the different routes of administration.
However, the outcome measures are largely objective
and there is a low likelihood of bias.
Conclusions
Post ingestion time is an important determinant of pre-
ferred antidotal therapy for acute paracetamol poisoning
patients in Sri Lanka. Using N-acetylcysteine in all
patients is not cost effective.
If policy makers are wishing to utilise economic eva-
luations to improve decision making, the findings from
this study suggest that, within the first 10 hours, the use
of methionine may be more cost-effective than NAC for
paracetamol poisoning in Sri Lanka. This would poten-
tially more than halve the total expenditure on this
increasingly common poisoning. N-acetylcysteine should
continue to be given to patients treated within 10-24
hours.
Limitations
The study recommends the use of methionine for
patients treated within 10 hours of the acute ingestion.
There is some literature suggestive of methionine induce
adverse effects such as nausea and vomiting. However
our prospective case series didn’t identify such inci-
dences even though 55 patients received methionine
compared 68 of IV NAC. Two patients received both
antidotes owing to unavailability of IV NAC at the time
of patient admission [3].
Additional material
Additional file 1: Annexure 1. Cost per patient (body weight: 60 kg) for
different treatment alternatives.
Additional file 2: Annexure 2. Summary of the studies included in the
exploratory analysis of the systematic review [9-21].
Abbreviations
GDP: Gross domestic product; NHSL: National Hospital of Sri Lanka; NAC: N-
acetylcysteine; ALT: Serum alanine aminotransferase; AST: Serum aspartate
aminotransferase; LKR: Sri Lankan rupees; RCTs: Randomised controlled trials;
ICER: Incremental cost effectiveness ratio.
Acknowledgements
The authors are grateful to director and the consultant physicians of the
NHSL for providing facility to carry out the study in the hospital. We are also
thankful to medical, nursing and other staff of medical wards and staff of
record room, accounts, salaries, and transport divisions of NHSL for
providing assistance to do the data collection. We are also thankful to
Professor Andrew Dawson and South Asian Clinical Toxicology Research
Collaboration for funding.
Author details
1Department of Pharmacology, Faculty of Medicine, University of Colombo,
Colombo, Sri Lanka.
2South Asian Clinical Toxicology Research Collaboration,
Kandy, Sri Lanka.
3Pharmacy Program, Department of Medical Education and
Health Sciences, Faculty of Medical Sciences, University of Sri
Jayewardenepura, Nugegoda , Sri Lanka.
4Faculty of Medicine, University of
New South Wales, Sydney, Australia.
Authors’ contributions
SMDKGS participated in the design and planning of the study, drafted the
study proposal, collected patient information, conducted the economic
evaluation and interpreted results, wrote the first draft and took part in
revising the paper and finalizing the paper. SSR participated in the design
and planning of the study, edited and revised the study proposal, edited the
paper and took part in revising the paper and approved the final version.
NB participated in the design and planning of the study, edited and revised
the study proposal, edited the paper and took part in revising the paper
and approved the final version. RF participated in the design and planning
of the study, edited and revised the study proposal, edited the paper and
took part in revising the paper and approved the final version. All authors
read and approved the final manuscript.
Study design
Cost effectiveness analysis based on exploratory analysis of a systematic
review
Competing interests
The authors declare that they have no competing interests.
Received: 25 February 2010 Accepted: 22 February 2012
Published: 22 February 2012
References
1. Sanaei-Zadeh H, Tagghaddosinejad F, Jalali N, Kariman H: Adverse effects
of intravenous N-acetylcysteine. Clin Drug Investig 2003, 23(2):129-133.
2. Buckley N, Eddleston M: Paracetamol (acetaminophen) poisoning. Clin
Evid 2005, 14:1738-1744.
3. Senarathna SMDKG, Sri Ranganathan S, Dawson AH, Buckley N,
Fernandopulle BMR: Management of acute paracetamol poisoning
patients in a tertiary care hospital. Ceylon Med J 2008, 53(3):89-92.
4. Wickramasinghe K, Steele P, Dawson A, Dharmaratne D, Gunawardena A,
Senarathna L, et al: Cost to government health-care services of treating
acute self-poisonings in a rural district in Sri Lanka. Bull World Health
Organ 2009, 87:180-185.
5. Senarathna SMDKG, Sri Ranganathan S, Fernandopulle BMR: Cost-outcome
description of management of patients with acute paracetamol
poisoning [Abstract]. Ceylon Med J 2008, 53(Suppl 1):53.
6. Brok J, Buckley N, Gluud C: Interventions for paracetamol
(acetaminophen) overdoses. Cochrane Database Syst Rev 2002, 3,
doi:10.1002/14651858.CD003328. Art No: CD003328.
7. Brok J, Buckley N, Gluud C: Interventions for paracetamol
(acetaminophen) overdoses (Review). Cochrane Database Systemic Review
2006, 2, doi:10.1002/14651858.CD003328.pub2. Art. No.: CD003328.
8. Investing in Health: World Development Report Oxford: Oxford. University
Press; 1993, 213-25, Ref Type: Report.
9. Prescott LF, Illingworth RN, Critchely JA, Stewart MJA, Proud foot AT:
Intravenous Nacetylcysteine: the treatment of choice for paracetamol
poisoning. Br Med J 1979, 2(6198):1097-1100.
10. Smilkstein MJ, Knapp GI, Kulig KW, Rumack BH: Efficacy of oral
Nacetylcysteine in the treatment of acetaminophen overdose. Analysis
of a national multi centre study (1976-1985). N Engl J Med 1988,
319(24):1557-1562.
11. Burkhart KK, Janco N, Kulig KW, Rumack BH: Cimetidine as adjunctive
treatment for acetaminophen overdose. Hum Exp Toxicol 1995, 14(3):299-304.
12. Buckley NA, Whyte IM, O’Connell DL, Dawson AH: Oral or intravenous
Nacetylcysteine: which is the treatment of choice for acetaminophen
(paracetamol) poisoning. J Toxicol Clin Toxicol 1999, 37(6):759-767.
13. Parker D, White P, Paton D, Routledge A: Safety of late acetylcysteine
treatment in paracetamol poisoning. Hum Exp Toxicol 1990, 9:25-27.
14. Smilkstein MJ, Bronskin AC, Linden C, Augenstein WL, Kulig KW, Rumack BH:
Acetaminophen overdose: A 48-h intravenous N-acetylcysteine
treatment protocol. Ann Emerg Med 1991, 20:1058-1063.
15. Woo OF, Mueller PD, Olson KR, Anderson IB, Kim SY: Shorter duration of
oral N-acetylcysteine therapy for acute acetaminophen overdose. Ann
Emerg Med 2000, 35(4):363-368.
Senarathna et al. BMC Clinical Pharmacology 2012, 12:6
http://www.biomedcentral.com/1472-6904/12/6
Page 6 of 716. Ayonrinde OT, Phelps GJ, Hurley JC, Ayonrinde OA: Paracetamol overdose
and hepatotoxicity at a regional Australian hospital: a 4 year experience.
Intern Med J 2005, 35:655-660.
17. Kerr F, Dawson A, Whyte IM, Buckley N, Murray L, Graudins A, et al: The
Australian clinical toxicology Investigators collaboration, Randomised
Trails of Different loading infusion rates of Nacetylcysteine. Ann Emerg
Med 2005, 45(4):402-408.
18. Crome P, Valem JA, Volans GN, Widdop B, Goulding R: Oral methionine in
the treatment of severe paracetamol (Acetaminophen) overdose. Lancet
1976, 2(7990):829-830.
19. Hamlyn AN, Lesna M, Record CO, Smith PA, Path FRC, Watson AJ:
Methionine and cysteamine in paracetamol overdose, prospective
controlled trial of early therapy. J Int Med Res 1981, 9:226-231.
20. Prescott LF, Park J, Sutherland GR, Smith IJ: Cysteamine, methionine, and
penicillamine in the treatment of paracetamol poisoning. Lancet 1976,
2:109-113.
21. Vale JA, Meredith TJ, Goulding R: Treatment of acetaminophen poisoning.
The use of oral methionine. Arch Intern Med 1981, 141(3):394-396.
22. National Institute for Clinical Excellence (NICE): Guide to the methods of
technology appraisal London London: NICE; 2004.
23. Census and statistics Sri Lanka: Household income and expenditure
survey 2006/07 summary findings. [On line]. Department of Census and
statistics Sri Lanka 2007, Available at: http://www.statistics.gov.lk/HIES/
HIES2006_07Website/Publications/SummaryFfindingsHIES2006_07.pdf
[Accessed on 1st April 2008].
24. Cook DJ, Guyatt GH, Laupacis A, Sackett DL: Rules of evidence and clinical
recommendations on the use of antithrombitic agents. Chest 1992,
102:305s-311s.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6904/12/6/prepub
doi:10.1186/1472-6904-12-6
Cite this article as: Senarathna et al.: A cost effectiveness analysis of the
preferred antidotes for acute paracetamol poisoning patients in Sri
Lanka. BMC Clinical Pharmacology 2012 12:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Senarathna et al. BMC Clinical Pharmacology 2012, 12:6
http://www.biomedcentral.com/1472-6904/12/6
Page 7 of 7